Viz.ai Gets FDA Clearance for New RV/LV Ratio Algorithm
The automated measurement of heart ventricle diameters and detection of potential dilation in the right ventricle may facilitate quicker intervention in cases of pulmonary embolism.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a new artificial-intelligence (AI)-powered RV/LV ratio algorithm, the latest addition to the Viz PE (pulmonary embolism) solution platform from Viz.ai.
Through automated measurement of the diameters of heart ventricles, the RV/LV ratio algorithm enables clinicians to quickly determine the ratio of maximum right ventricle diameter to that of the left ventricle, according to Viz.ai.
Kenneth Rosenfield, M.D., said the latest addition to the Viz.ai Platform is a significant advance in facilitating timely risk stratification and care in patients with pulmonary embolism (PE). The algorithm’s ability to assess potential issues with right ventricle dilation is a key benefit, according to Dr. Rosenfield, an interventional cardiologist and section head of Vascular Medicine and Intervention at the Massachusetts General Hospital in Boston.
“The true killer in patients with (pulmonary embolism) is failure of the right heart. With this clearance, the VIZ PE Solution now includes both detection of clot in the lungs and degree of strain on the heart,” said Dr. Rosenfield. “This will enable clinicians to quickly triage patients and treat them appropriately by providing a powerful tool for early detection and risk stratification. This expedited critical decision-making will undoubtedly save lives.”
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
